-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the latest data from Meinenet.
com on April 12, the market size of the terminal Chinese patent medicine in public hospitals in key cities in 2020 is nearly 30 billion yuan, a year-on-year decrease of 12.
48%.
The sales of 46 exclusive Chinese patent medicines exceeded 100 million yuan (8 over 3 billion yuan).
Billion), with a total sales scale of nearly 10 billion yuan, with the largest number of cardio-cerebral vascular drugs; 10 exclusive Chinese patent medicines rose against the trend, and 2 varieties soared by more than 50%; 46 exclusive Chinese patent medicines involved 36 companies, Yiling, Step, Yangtze River, Jichuan.
.
.
6 companies are on.
com on April 12, the market size of the terminal Chinese patent medicine in public hospitals in key cities in 2020 is nearly 30 billion yuan, a year-on-year decrease of 12.
48%.
The sales of 46 exclusive Chinese patent medicines exceeded 100 million yuan (8 over 3 billion yuan).
Billion), with a total sales scale of nearly 10 billion yuan, with the largest number of cardio-cerebral vascular drugs; 10 exclusive Chinese patent medicines rose against the trend, and 2 varieties soared by more than 50%; 46 exclusive Chinese patent medicines involved 36 companies, Yiling, Step, Yangtze River, Jichuan.
.
.
6 companies are on.
Exclusive Chinese patent medicine with over 100 million terminal sales in public hospitals in key cities
Source: Mi Nei.
com's key city public hospital terminal competition pattern
com's key city public hospital terminal competition pattern
According to data from Meinenet, the total sales volume of 46 exclusive Chinese patent medicines (in terms of drug names, including exclusive formulations) with sales of over 100 million yuan in public hospitals in key cities in 2020 will be close to 10 billion yuan.
Of the 46 exclusive proprietary Chinese medicines, 43 are national medical insurance products of the 2020 version, of which 13 are Class A medical insurance products and 30 are Class B medical insurance products.
Tengyao Pharmaceutical's Xinmailong injection is a new variety; in addition, 19 exclusive Chinese patent medicines are the 2018 version of the national basic medicine variety.
Tengyao Pharmaceutical's Xinmailong injection is a new variety; in addition, 19 exclusive Chinese patent medicines are the 2018 version of the national basic medicine variety.
8 exclusive Chinese patent medicines exceed 300 million yuan, and 19 cardiovascular and cerebrovascular medicines lead the tens of billions market
Kanglaite Injection, Bailing Capsules, Danshen Polyphenolate for Injection, Jinshuibao Tablets, Kangai Injection, Danhong Injection, Lanqin Oral Liquid, Suhuang Cough Capsules 8 exclusive proprietary Chinese medicines in key cities in 2020 The terminal sales of public hospitals exceeded 300 million yuan, of which Kanglaite injections and Bailing capsules exceeded 500 million yuan.
The Kanglaite injection of Zhejiang Kanglaite Pharmaceutical has the effects of replenishing qi and nourishing yin, eliminating symptoms and dispelling masses, and is suitable for primary non-small cell lung cancer and primary liver cancer with deficiency of both qi and yin, spleen deficiency and dampness type that are not suitable for surgery.
In 2017, the product surpassed Kangai injection and became the best-selling anti-tumor Chinese patent medicine at the terminal of public hospitals in key cities.
In 2017, the product surpassed Kangai injection and became the best-selling anti-tumor Chinese patent medicine at the terminal of public hospitals in key cities.
46 exclusive Chinese patent medicine drug treatment categories
46 exclusive Chinese patent medicines cover 10 treatment categories, and the central cerebrovascular disease drugs are the top, with a total of 19 varieties, accounting for 41.
31%; tumor disease drugs ranked second with 15.
22%, involving 7 varieties; Drugs for respiratory diseases ranked third with 13.
04%, involving 6 varieties.
31%; tumor disease drugs ranked second with 15.
22%, involving 7 varieties; Drugs for respiratory diseases ranked third with 13.
04%, involving 6 varieties.
10 exclusive Chinese patent medicines rose against the trend, these 2 rose by more than 50%
In 2020, the market size of proprietary Chinese medicines in public hospitals in key cities will be close to 30 billion yuan, a year-on-year decline of 12.
48%.
Among 46 exclusive Chinese patent medicines with sales over 100 million, Lianhua Qingwen Granules, Compound Kushen Injection, Shuganning Injection, Shengxuebao Mixture, Jinshuibao Tablets, Xingxiong Sodium Chloride Injection, Shensongyangxin Capsules , Xuezhikang Capsules, Shexiang Baoxin Pills, and Suxiao Jiuxin Pills bucked the trend.
Among them, Lianhua Qingwen Granules and Xingxiong Sodium Chloride Injection rose by more than 50%; the growth rate of many exclusive Chinese patent medicines declined, among which Chengdu Baiyu The pharmaceutical ginkgolide injection dropped by more than 50%.
48%.
Among 46 exclusive Chinese patent medicines with sales over 100 million, Lianhua Qingwen Granules, Compound Kushen Injection, Shuganning Injection, Shengxuebao Mixture, Jinshuibao Tablets, Xingxiong Sodium Chloride Injection, Shensongyangxin Capsules , Xuezhikang Capsules, Shexiang Baoxin Pills, and Suxiao Jiuxin Pills bucked the trend.
Among them, Lianhua Qingwen Granules and Xingxiong Sodium Chloride Injection rose by more than 50%; the growth rate of many exclusive Chinese patent medicines declined, among which Chengdu Baiyu The pharmaceutical ginkgolide injection dropped by more than 50%.
Honghe Pharmaceutical’s Xingxiong Sodium Chloride Injection is a compound preparation composed of ginkgo biloba extract and ligustrazine phosphate, which can antagonize oxygen free radicals, protect ischemic cells, anticoagulant and antithrombotic, promote the opening of collateral circulation, improve microcirculation, etc.
Efficacy, suitable for ischemic cardiovascular and cerebrovascular diseases (such as cerebral insufficiency, cerebral embolism, angina, etc.
), brain insufficiency, senile dementia, pharmnet.
com.
cn/pharmnet/200610/hbp/" target="_blank">hypertension , hyperlipidemia, etc.
Efficacy, suitable for ischemic cardiovascular and cerebrovascular diseases (such as cerebral insufficiency, cerebral embolism, angina, etc.
), brain insufficiency, senile dementia, pharmnet.
com.
cn/pharmnet/200610/hbp/" target="_blank">hypertension , hyperlipidemia, etc.
Sales of Xingxiong Sodium Chloride Injection in Terminals of Public Hospitals in Key Cities
Source: Mi Nei.
com's key city public hospital terminal competition pattern
com's key city public hospital terminal competition pattern
In recent years, the sales of Xingxiong Sodium Chloride Injection in public hospitals in key cities have increased year by year, and the growth rate in 2020 will be close to 60%.
At present, the product has not been included in the national medical insurance, nor is it a national basic drug product .
At present, the product has not been included in the national medical insurance, nor is it a national basic drug product .
Sales of Lianhua Qingwen at the terminal of public hospitals in key cities
Yiling Pharmaceutical's Lianhua Qingwen series products (including capsules and granules) were approved in April 2020 for the routine treatment of new coronary pneumonia.
Driven by the sales of epidemic prevention and control drugs, the sales of Lianhua Qingwen in public hospitals in key cities will increase by 54.
03% in 2020, of which the sales of Lianhua Qingwen granules accounted for 95%.
Driven by the sales of epidemic prevention and control drugs, the sales of Lianhua Qingwen in public hospitals in key cities will increase by 54.
03% in 2020, of which the sales of Lianhua Qingwen granules accounted for 95%.
6 companies are eye-catching, Yiling, Shangyao, Yangtze River.
.
.
.
.
46 exclusive proprietary involving 36 pharmaceutical companies (the Group dollars), which Yiling Pharmaceutical, step pharmaceuticals, the Pharmaceutical Group, Jichuanjian medicine, Yangtze River, Changbai six pharmaceutical companies count involving two or more varieties .
An enterprise that has sold over 100 million exclusive Chinese patent medicines with 2 or more varieties
Yiling Pharmaceutical’s Lianhua Qingwen Granules, Tongxinluo Capsules, Shensongyangxin Capsules, and Qiliqiangxin Capsules are all National Medical Insurance Class A and National Basic Drugs.
Except for Lianhua Qingwen Granules, the other 3 types are all Medication for cardiovascular and cerebrovascular diseases .
Except for Lianhua Qingwen Granules, the other 3 types are all Medication for cardiovascular and cerebrovascular diseases .
Buchang Pharmaceutical’s Danhong Injection, Naoxintong Capsules, and Wenxin Granules are all medicines for cardiovascular and cerebrovascular diseases.
The three exclusive Chinese patent medicines are all medical insurance products.
Among them, Naoxintong Capsules and Wenxin Granules are the national basic medicines.
Variety.
According to data from Minaiwang, Buchang Pharmaceuticals takes the lead in the ranking of terminal cardiovascular and cerebrovascular disease drug manufacturers in public hospitals in key cities in 2020 .
The three exclusive Chinese patent medicines are all medical insurance products.
Among them, Naoxintong Capsules and Wenxin Granules are the national basic medicines.
Variety.
According to data from Minaiwang, Buchang Pharmaceuticals takes the lead in the ranking of terminal cardiovascular and cerebrovascular disease drug manufacturers in public hospitals in key cities in 2020 .
Shanghai Pharmaceutical Group's Shexiang Baoxin Pills, Tanshinone ⅡA Sodium Sulfonate Injection, and Gualoupi Injection are also used for cardiovascular and cerebrovascular diseases.
Among them, Shexiang Baoxin Pills are National Medical Insurance Class A and National Basic Drugs, and will be sold in 2020.
The growth rate exceeds 15%.
Among them, Shexiang Baoxin Pills are National Medical Insurance Class A and National Basic Drugs, and will be sold in 2020.
The growth rate exceeds 15%.
The sales of Suhuang Cough Capsule and Lanqin Oral Liquid of Yangtze River in public hospitals in key cities in 2020 will each exceed 300 million yuan, ranking 10.
06% in the two categories of respiratory disease drugs and ENT drugs.
, The market share of 36.
8% ranks first.
06% in the two categories of respiratory disease drugs and ENT drugs.
, The market share of 36.
8% ranks first.
Source: Minet database
According to the latest data from Meinenet.
com on April 12, the market size of the terminal Chinese patent medicine in public hospitals in key cities in 2020 is nearly 30 billion yuan, a year-on-year decrease of 12.
48%.
The sales of 46 exclusive Chinese patent medicines exceeded 100 million yuan (8 over 3 billion yuan).
Billion), with a total sales scale of nearly 10 billion yuan, with the largest number of cardio-cerebral vascular drugs; 10 exclusive Chinese patent medicines rose against the trend, and 2 varieties soared by more than 50%; 46 exclusive Chinese patent medicines involved 36 companies, Yiling, Step, Yangtze River, Jichuan.
.
.
6 companies are on.
com on April 12, the market size of the terminal Chinese patent medicine in public hospitals in key cities in 2020 is nearly 30 billion yuan, a year-on-year decrease of 12.
48%.
The sales of 46 exclusive Chinese patent medicines exceeded 100 million yuan (8 over 3 billion yuan).
Billion), with a total sales scale of nearly 10 billion yuan, with the largest number of cardio-cerebral vascular drugs; 10 exclusive Chinese patent medicines rose against the trend, and 2 varieties soared by more than 50%; 46 exclusive Chinese patent medicines involved 36 companies, Yiling, Step, Yangtze River, Jichuan.
.
.
6 companies are on.
Exclusive Chinese patent medicine with over 100 million terminal sales in public hospitals in key cities
Source: Mi Nei.
com's key city public hospital terminal competition pattern
com's key city public hospital terminal competition pattern
According to data from Meinenet, the total sales volume of 46 exclusive Chinese patent medicines (in terms of drug names, including exclusive formulations) with sales of over 100 million yuan in public hospitals in key cities in 2020 will be close to 10 billion yuan.
Of the 46 exclusive proprietary Chinese medicines, 43 are national medical insurance products of the 2020 version, of which 13 are Class A medical insurance products and 30 are Class B medical insurance products.
Tengyao Pharmaceutical's Xinmailong injection is a new variety; in addition, 19 exclusive Chinese patent medicines are the 2018 version of the national basic medicine variety.
Tengyao Pharmaceutical's Xinmailong injection is a new variety; in addition, 19 exclusive Chinese patent medicines are the 2018 version of the national basic medicine variety.
8 exclusive Chinese patent medicines exceed 300 million yuan, and 19 cardiovascular and cerebrovascular medicines lead the tens of billions market
Kanglaite Injection, Bailing Capsules, Danshen Polyphenolate for Injection, Jinshuibao Tablets, Kangai Injection, Danhong Injection, Lanqin Oral Liquid, Suhuang Cough Capsules 8 exclusive proprietary Chinese medicines in key cities in 2020 The terminal sales of public hospitals exceeded 300 million yuan, of which Kanglaite injections and Bailing capsules exceeded 500 million yuan.
The Kanglaite injection of Zhejiang Kanglaite Pharmaceutical has the effects of replenishing qi and nourishing yin, eliminating symptoms and dispelling masses, and is suitable for primary non-small cell lung cancer and primary liver cancer with deficiency of both qi and yin, spleen deficiency and dampness type that are not suitable for surgery.
In 2017, the product surpassed Kangai injection and became the best-selling anti-tumor Chinese patent medicine at the terminal of public hospitals in key cities.
In 2017, the product surpassed Kangai injection and became the best-selling anti-tumor Chinese patent medicine at the terminal of public hospitals in key cities.
46 exclusive Chinese patent medicine drug treatment categories
46 exclusive Chinese patent medicines cover 10 treatment categories, and the central cerebrovascular disease drugs are the top, with a total of 19 varieties, accounting for 41.
31%; tumor disease drugs ranked second with 15.
22%, involving 7 varieties; Drugs for respiratory diseases ranked third with 13.
04%, involving 6 varieties.
31%; tumor disease drugs ranked second with 15.
22%, involving 7 varieties; Drugs for respiratory diseases ranked third with 13.
04%, involving 6 varieties.
10 exclusive Chinese patent medicines rose against the trend, these 2 rose by more than 50%
In 2020, the market size of proprietary Chinese medicines in public hospitals in key cities will be close to 30 billion yuan, a year-on-year decline of 12.
48%.
Among 46 exclusive Chinese patent medicines with sales over 100 million, Lianhua Qingwen Granules, Compound Kushen Injection, Shuganning Injection, Shengxuebao Mixture, Jinshuibao Tablets, Xingxiong Sodium Chloride Injection, Shensongyangxin Capsules , Xuezhikang Capsules, Shexiang Baoxin Pills, and Suxiao Jiuxin Pills bucked the trend.
Among them, Lianhua Qingwen Granules and Xingxiong Sodium Chloride Injection rose by more than 50%; the growth rate of many exclusive Chinese patent medicines declined, among which Chengdu Baiyu The pharmaceutical ginkgolide injection dropped by more than 50%.
48%.
Among 46 exclusive Chinese patent medicines with sales over 100 million, Lianhua Qingwen Granules, Compound Kushen Injection, Shuganning Injection, Shengxuebao Mixture, Jinshuibao Tablets, Xingxiong Sodium Chloride Injection, Shensongyangxin Capsules , Xuezhikang Capsules, Shexiang Baoxin Pills, and Suxiao Jiuxin Pills bucked the trend.
Among them, Lianhua Qingwen Granules and Xingxiong Sodium Chloride Injection rose by more than 50%; the growth rate of many exclusive Chinese patent medicines declined, among which Chengdu Baiyu The pharmaceutical ginkgolide injection dropped by more than 50%.
Honghe Pharmaceutical’s Xingxiong Sodium Chloride Injection is a compound preparation composed of ginkgo biloba extract and ligustrazine phosphate, which can antagonize oxygen free radicals, protect ischemic cells, anticoagulant and antithrombotic, promote the opening of collateral circulation, improve microcirculation, etc.
Efficacy, suitable for ischemic cardiovascular and cerebrovascular diseases (such as cerebral insufficiency, cerebral embolism, angina, etc.
), brain insufficiency, senile dementia, pharmnet.
com.
cn/pharmnet/200610/hbp/" target="_blank">hypertension , hyperlipidemia, etc.
Efficacy, suitable for ischemic cardiovascular and cerebrovascular diseases (such as cerebral insufficiency, cerebral embolism, angina, etc.
), brain insufficiency, senile dementia, pharmnet.
com.
cn/pharmnet/200610/hbp/" target="_blank">hypertension , hyperlipidemia, etc.
Sales of Xingxiong Sodium Chloride Injection in Terminals of Public Hospitals in Key Cities
Source: Mi Nei.
com's key city public hospital terminal competition pattern
com's key city public hospital terminal competition pattern
In recent years, the sales of Xingxiong Sodium Chloride Injection in public hospitals in key cities have increased year by year, and the growth rate in 2020 will be close to 60%.
At present, the product has not been included in the national medical insurance, nor is it a national basic drug product .
At present, the product has not been included in the national medical insurance, nor is it a national basic drug product .
Sales of Lianhua Qingwen at the terminal of public hospitals in key cities
Yiling Pharmaceutical's Lianhua Qingwen series products (including capsules and granules) were approved in April 2020 for the routine treatment of new coronary pneumonia.
Driven by the sales of epidemic prevention and control drugs, the sales of Lianhua Qingwen in public hospitals in key cities will increase by 54.
03% in 2020, of which the sales of Lianhua Qingwen granules accounted for 95%.
Driven by the sales of epidemic prevention and control drugs, the sales of Lianhua Qingwen in public hospitals in key cities will increase by 54.
03% in 2020, of which the sales of Lianhua Qingwen granules accounted for 95%.
6 companies are eye-catching, Yiling, Shangyao, Yangtze River.
.
.
.
.
46 exclusive proprietary involving 36 pharmaceutical companies (the Group dollars), which Yiling Pharmaceutical, step pharmaceuticals, the Pharmaceutical Group, Jichuanjian medicine, Yangtze River, Changbai six pharmaceutical companies count involving two or more varieties .
An enterprise that has sold over 100 million exclusive Chinese patent medicines with 2 or more varieties
Yiling Pharmaceutical’s Lianhua Qingwen Granules, Tongxinluo Capsules, Shensongyangxin Capsules, and Qiliqiangxin Capsules are all National Medical Insurance Class A and National Basic Drugs.
Except for Lianhua Qingwen Granules, the other 3 types are all Medication for cardiovascular and cerebrovascular diseases .
Except for Lianhua Qingwen Granules, the other 3 types are all Medication for cardiovascular and cerebrovascular diseases .
Buchang Pharmaceutical’s Danhong Injection, Naoxintong Capsules, and Wenxin Granules are all medicines for cardiovascular and cerebrovascular diseases.
The three exclusive Chinese patent medicines are all medical insurance products.
Among them, Naoxintong Capsules and Wenxin Granules are the national basic medicines.
Variety.
According to data from Minaiwang, Buchang Pharmaceuticals takes the lead in the ranking of terminal cardiovascular and cerebrovascular disease drug manufacturers in public hospitals in key cities in 2020 .
The three exclusive Chinese patent medicines are all medical insurance products.
Among them, Naoxintong Capsules and Wenxin Granules are the national basic medicines.
Variety.
According to data from Minaiwang, Buchang Pharmaceuticals takes the lead in the ranking of terminal cardiovascular and cerebrovascular disease drug manufacturers in public hospitals in key cities in 2020 .
Shanghai Pharmaceutical Group's Shexiang Baoxin Pills, Tanshinone ⅡA Sodium Sulfonate Injection, and Gualoupi Injection are also used for cardiovascular and cerebrovascular diseases.
Among them, Shexiang Baoxin Pills are National Medical Insurance Class A and National Basic Drugs, and will be sold in 2020.
The growth rate exceeds 15%.
Among them, Shexiang Baoxin Pills are National Medical Insurance Class A and National Basic Drugs, and will be sold in 2020.
The growth rate exceeds 15%.
The sales of Suhuang Cough Capsule and Lanqin Oral Liquid of Yangtze River in public hospitals in key cities in 2020 will each exceed 300 million yuan, ranking 10.
06% in the two categories of respiratory disease drugs and ENT drugs.
, The market share of 36.
8% ranks first.
06% in the two categories of respiratory disease drugs and ENT drugs.
, The market share of 36.
8% ranks first.
Source: Minet database
According to the latest data from Meinenet.
com on April 12, the market size of the terminal Chinese patent medicine in public hospitals in key cities in 2020 is nearly 30 billion yuan, a year-on-year decrease of 12.
48%.
The sales of 46 exclusive Chinese patent medicines exceeded 100 million yuan (8 over 3 billion yuan).
Billion), with a total sales scale of nearly 10 billion yuan, with the largest number of cardio-cerebral vascular drugs; 10 exclusive Chinese patent medicines rose against the trend, and 2 varieties soared by more than 50%; 46 exclusive Chinese patent medicines involved 36 companies, Yiling, Step, Yangtze River, Jichuan.
.
.
6 companies are on.
com on April 12, the market size of the terminal Chinese patent medicine in public hospitals in key cities in 2020 is nearly 30 billion yuan, a year-on-year decrease of 12.
48%.
The sales of 46 exclusive Chinese patent medicines exceeded 100 million yuan (8 over 3 billion yuan).
Billion), with a total sales scale of nearly 10 billion yuan, with the largest number of cardio-cerebral vascular drugs; 10 exclusive Chinese patent medicines rose against the trend, and 2 varieties soared by more than 50%; 46 exclusive Chinese patent medicines involved 36 companies, Yiling, Step, Yangtze River, Jichuan.
.
.
6 companies are on.
Exclusive Chinese patent medicine with over 100 million terminal sales in public hospitals in key cities
Source: Mi Nei.
com's key city public hospital terminal competition pattern
com's key city public hospital terminal competition pattern
According to data from Meinenet, the total sales volume of 46 exclusive Chinese patent medicines (in terms of drug names, including exclusive formulations) with sales of over 100 million yuan in public hospitals in key cities in 2020 will be close to 10 billion yuan.
Of the 46 exclusive proprietary Chinese medicines, 43 are national medical insurance products of the 2020 version, of which 13 are Class A medical insurance products and 30 are Class B medical insurance products.
Tengyao Pharmaceutical's Xinmailong injection is a new variety; in addition, 19 exclusive Chinese patent medicines are the 2018 version of the national basic medicine variety.
Tengyao Pharmaceutical's Xinmailong injection is a new variety; in addition, 19 exclusive Chinese patent medicines are the 2018 version of the national basic medicine variety.
8 exclusive Chinese patent medicines exceed 300 million yuan, and 19 cardiovascular and cerebrovascular medicines lead the tens of billions market
8 exclusive Chinese patent medicines exceed 300 million yuan, and 19 cardiovascular and cerebrovascular medicines lead the tens of billions market Kanglaite Injection, Bailing Capsules, Danshen Polyphenolate for Injection, Jinshuibao Tablets, Kangai Injection, Danhong Injection, Lanqin Oral Liquid, Suhuang Cough Capsules 8 exclusive proprietary Chinese medicines in key cities in 2020 The terminal sales of public hospitals exceeded 300 million yuan, of which Kanglaite injections and Bailing capsules exceeded 500 million yuan.
The Kanglaite injection of Zhejiang Kanglaite Pharmaceutical has the effects of replenishing qi and nourishing yin, eliminating symptoms and dispelling masses, and is suitable for primary non-small cell lung cancer and primary liver cancer with deficiency of both qi and yin, spleen deficiency and dampness type that are not suitable for surgery.
In 2017, the product surpassed Kangai injection and became the best-selling anti-tumor Chinese patent medicine at the terminal of public hospitals in key cities.
In 2017, the product surpassed Kangai injection and became the best-selling anti-tumor Chinese patent medicine at the terminal of public hospitals in key cities.
46 exclusive Chinese patent medicine drug treatment categories
46 exclusive Chinese patent medicines cover 10 treatment categories, and the central cerebrovascular disease drugs are the top, with a total of 19 varieties, accounting for 41.
31%; tumor disease drugs ranked second with 15.
22%, involving 7 varieties; Drugs for respiratory diseases ranked third with 13.
04%, involving 6 varieties.
31%; tumor disease drugs ranked second with 15.
22%, involving 7 varieties; Drugs for respiratory diseases ranked third with 13.
04%, involving 6 varieties.
10 exclusive Chinese patent medicines rose against the trend, these 2 rose by more than 50%
10 exclusive Chinese patent medicines rose against the trend, these 2 rose by more than 50% In 2020, the market size of proprietary Chinese medicines in public hospitals in key cities will be close to 30 billion yuan, a year-on-year decline of 12.
48%.
Among 46 exclusive Chinese patent medicines with sales over 100 million, Lianhua Qingwen Granules, Compound Kushen Injection, Shuganning Injection, Shengxuebao Mixture, Jinshuibao Tablets, Xingxiong Sodium Chloride Injection, Shensongyangxin Capsules , Xuezhikang Capsules, Shexiang Baoxin Pills, and Suxiao Jiuxin Pills bucked the trend.
Among them, Lianhua Qingwen Granules and Xingxiong Sodium Chloride Injection rose by more than 50%; the growth rate of many exclusive Chinese patent medicines declined, among which Chengdu Baiyu The pharmaceutical ginkgolide injection dropped by more than 50%.
48%.
Among 46 exclusive Chinese patent medicines with sales over 100 million, Lianhua Qingwen Granules, Compound Kushen Injection, Shuganning Injection, Shengxuebao Mixture, Jinshuibao Tablets, Xingxiong Sodium Chloride Injection, Shensongyangxin Capsules , Xuezhikang Capsules, Shexiang Baoxin Pills, and Suxiao Jiuxin Pills bucked the trend.
Among them, Lianhua Qingwen Granules and Xingxiong Sodium Chloride Injection rose by more than 50%; the growth rate of many exclusive Chinese patent medicines declined, among which Chengdu Baiyu The pharmaceutical ginkgolide injection dropped by more than 50%.
Honghe Pharmaceutical’s Xingxiong Sodium Chloride Injection is a compound preparation composed of ginkgo biloba extract and ligustrazine phosphate, which can antagonize oxygen free radicals, protect ischemic cells, anticoagulant and antithrombotic, promote the opening of collateral circulation, improve microcirculation, etc.
Efficacy, suitable for ischemic cardiovascular and cerebrovascular diseases (such as cerebral insufficiency, cerebral embolism, angina, etc.
), brain insufficiency, senile dementia, pharmnet.
com.
cn/pharmnet/200610/hbp/" target="_blank">hypertension , hyperlipidemia, etc.
pharmnet. Efficacy, suitable for ischemic cardiovascular and cerebrovascular diseases (such as cerebral insufficiency, cerebral embolism, angina, etc.
), brain insufficiency, senile dementia, pharmnet.
com.
cn/pharmnet/200610/hbp/" target="_blank">hypertension , hyperlipidemia, etc.
com.
cn/pharmnet/200610/hbp/" target="_blank">Hypertensionpharmnet.
com.
cn/pharmnet/200610/hbp/" target="_blank"> hypertension hypertension
Sales of Xingxiong Sodium Chloride Injection in Terminals of Public Hospitals in Key Cities
Source: Mi Nei.
com's key city public hospital terminal competition pattern
com's key city public hospital terminal competition pattern
，，202060%。，。
（）20204。，202054.
03%，95%。
03%，95%。
6，、、.
.
.
.
.
.
6，、、. .
.
.
.
.
.
.
.
.
.
4636（），、、、、、62。
2
、、、，，3。
、、，3，、。，2020，。
、ⅡA、，，202015%。
、20203，，10.
06%、36.
8%。
06%、36.
8%。
：
